MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cpt.2433

Медицинская библиотека · Clinical pharmacology and therapeutics · 2021

Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G-CSF, in Pediatric Patients with Solid Tumors.

Lee Soyoung, Hong Kyung Taek, Moon Seol Ju, Choi Jung Yoon, Hong Che Ry, Shin Hee Young, Cho Joo-Youn, Jang In-Jin, Yu Kyung-Sang, Oh Jaeseong, Kang Hyoung Jin

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

A long-acting granulocyte colony-stimulating factor, tripegfilgrastim, was approved in Korea for the prevention of chemotherapy-induced neutropenia in adult patients. In this study, we evaluated the pharmacokinetics, pharmacodynamics, and safety of tripegfilgrastim in pediatric patients. A phase I, open-label, single ascending-dose study was performed in pediatric patients with solid tumors or lymphoma (ClinicalTrials.gov, NCT02963389). The patients were stratified according to age groups (aged 6 to 12 or 12 to 19 years) and received a single subcutaneous dose of tripegfilgrastim 60 μg/kg or 100 μg/kg. Tripegfilgrastim was administered 24 hours after the end of the chemotherapy, and serial blood sampling and safety monitoring were conducted. Twenty-seven patients with solid tumors were enrolled in this study. Tripegfilgrastim was detectable in plasma for an extended period (terminal half-life > 40 hours), and plasma concentrations increased slightly less than dose proportionally. The mean duration of grade 4 neutropenia was reduced as the average tripegfilgrastim concentration during the initial neutrophil recovery process increased. No substantial differences in the pharmacokinetic and pharmacodynamic responses were observed between the two age groups. When stratified by body weight, weighing more than 45 kg has a higher risk of a prolonged neutropenia period when receiving the lower dose (60 μg/kg) of tripegfilgrastim. Tripegfilgrastim was generally safe and well-tolerated in the pediatric patients. These results justify further clinical investigations of tripegfilgrastim at 100 μg/kg dose in pediatric patients.

Для цитирования: Lee Soyoung, Hong Kyung Taek, Moon Seol Ju, Choi Jung Yoon, Hong Che Ry, Shin Hee Young, Cho Joo-Youn, Jang In-Jin, Yu Kyung-Sang, Oh Jaeseong, Kang Hyoung Jin. Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G-CSF, in Pediatric Patients with Solid Tumors.. Clinical pharmacology and therapeutics. 2021. DOI: 10.1002/cpt.2433.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.